证券日报网讯1月7日，爱尔眼科（300015）在互动平台回答投资者提问时表示，"小青葵"系列产品已实 现量产，具有良好的近视防控效果。 ...

证券日报网讯1月7日，爱尔眼科（300015）在互动平台回答投资者提问时表示，爱尔网络覆盖中国广大 城乡县域，截至2025年6月30日，公司境内医院355家，门诊部240家，详情请查阅爱尔眼科官网。 ...

格隆汇1月7日丨爱尔眼科(300015.SZ)在投资者互动平台表示，"小青葵"系列产品已实现量产。 ...

Core Viewpoint - The inclusion of the targeted drug Teprotumumab in the national medical insurance directory starting January 1, 2026, marks a significant advancement in the treatment of Thyroid Eye Disease (TED), providing financial relief for patients who previously faced high treatment costs [1][3]. Group 1: Drug and Treatment Details - Teprotumumab is the first domestically approved targeted therapy for TED, significantly reducing treatment costs from approximately 3 million yuan per course to under 6000 yuan per injection after insurance reimbursement [3][5]. - Patients like Ms. Li, who previously struggled with traditional treatments, can now access this innovative therapy, with personal costs reduced to 1909.12 yuan per injection after insurance [1][3]. Group 2: Clinical Impact and Patient Management - Early diagnosis and treatment are crucial for managing TED symptoms, which include eye bulging and vision impairment, potentially leading to severe complications [4]. - The Dongguan Aier Eye Hospital has established a specialized clinic for TED, offering comprehensive management from prevention to rehabilitation, ensuring tailored treatment plans for patients [5]. Group 3: Economic and Accessibility Implications - The inclusion of Teprotumumab in the insurance scheme signifies a new era of accessibility for TED treatment, allowing more patients to benefit from effective and safe targeted therapies [5]. - The policy change is expected to alleviate the financial burden on patients, enabling timely access to necessary treatments [5].

图为发布 会现场，STAAR公司代表与院方共同为"EVO ICL V5 晶体甘肃临床应用普及联盟成员单位"揭牌。 在安全性与适应人群方面，姚慧表示，V5晶体完全继承了前代产品的安全基石，其"新"主要体现在光 学设计优化。医院依托同步国际的40余项精密术前检查，严格实施"量眼定制"式评估，从源头确保手术 安全与效果。她指出，不同的近视矫正技术各具特点：激光类手术适用于中低度近视；全光塑手术可满 足航空人员等对视觉质量的极高要求；全飞秒微创特点适配参军等人群；而对于600度以上的高度近 视，特别是夜间驾驶需求者，EVO ICL(V5)凭借其扩大的光学区，能提供更优解决方案。 活动还邀请了术后患者代表分享体验，其关于夜间视力改善提升生活质量的真实故事，引起了现场观众 的共鸣。 中新网甘肃新闻1月7日电(崔琳)2026年1月6日，"链接全球，领衔未来！EVO ICL(V5)晶体植入术甘肃首 发发布会"举行。此次发布标志着这项全球前沿的近视矫正技术正式落地甘肃，省内近视患者无需远赴 外地，即可同步享受国际领先的"加法"屈光手术。 发布会上，甘肃爱尔眼视光医院及兰州爱尔眼科医院CEO、屈光科主任姚慧回顾了医院十三年来在屈 ...

2026年1月5日，博士伦公司事业部总监Garry Lau、国药瑞德医疗器材有限公司总经理朱鼎宏一行到访 华厦眼科。集团领导陈凤国携相关部门负责人热情接待，围绕眼病手术领域的技术革新、临床应用与服 务质量提升，展开深度座谈交流。此次战略对话旨在进一步深化战略合作，共同探索眼病手术诊疗新模 式，推动眼病服务向更高品质、更精准、更可及的方向迈进。 共叙合作情谊，共话发展愿景 集团领导陈凤国对博士伦与国药瑞德一行的到访表示热烈欢迎。他指出，"一切以病人为中心"是华厦眼 科始终不变的服务宗旨。"十四五"期间，我国CSR(每百万人白内障手术例数)不断提高，但较发达国家 仍有较大差距。从长远看，提升眼病手术的普及率与技术水平仍是行业重要使命。 他强调，提升眼病手术诊疗服务质量是双方共同的责任与追求，期待通过更全面的资源整合，探索高品 质眼病服务新路径，造福更多眼疾患者。 博士伦事业部总监Garry Lau深情回顾，博士伦与华厦眼科是22载的"老朋友"，彼此的信任早已根深叶 茂。他表示，华厦眼科拥有顶尖的专家团队、强大的临床实力与广泛的基层医疗网络覆盖能力，是国内 眼科医疗领域的佼佼者，也是博士伦创新产品的优先合作伙伴。 ...

证券日报网讯 1月6日，爱尔眼科在互动平台回答投资者提问时表示，公司专注眼科医疗，高度关注边 缘交叉学科的动态进展，在创新上鼓励"脑洞大开"，在工作中必须"脚踏实地"。 （文章来源：证券日报） ...

Group 1 - The company, Aier Eye Hospital (300015), focuses on its core business, providing multi-level ophthalmic diagnosis and treatment services for all age groups [1] - The company continuously monitors cutting-edge developments in marginal crossover fields [1]

智通财经APP讯，朝聚眼科(02219)发布公告，于2026年1月6日该公司斥资16.26万港元回购6万股，回购 价格为每股2.68-2.74港元。 ...

Core Viewpoint - The case of Dr. Li Jianhua against Chen, a social media influencer, highlights the judicial protection of citizens' reputation rights and aligns with the national effort to strengthen online governance and punish online crimes [1][9]. Group 1: Background of the Case - Chen, who had no prior connection to Dr. Li, began a campaign of online harassment against him following a medical dispute involving another party, resulting in over two years of defamation through social media [2][10]. - The defamatory statements included accusations of "academic fraud" and "practicing medicine without a license," leading to severe personal and professional consequences for Dr. Li, including mental health issues and disruption of the hospital's operations [2][10]. Group 2: Legal Proceedings - After unsuccessful attempts to resolve the issue amicably, Dr. Li filed a civil lawsuit in November 2021, which resulted in a court ruling against Chen for defamation, requiring him to delete the defamatory content and issue an apology [3][11]. - Despite the civil judgment, Chen continued to spread false information, further damaging Dr. Li's reputation and undermining public trust in the judicial system [3][11]. Group 3: Criminal Charges and Sentencing - Dr. Li subsequently pursued criminal charges against Chen, leading to a conviction for defamation, with the court determining that Chen's actions met the legal criteria for severe circumstances, including high engagement metrics on his defamatory posts [5][14]. - The court sentenced Chen to 18 months in prison, emphasizing the importance of upholding legal standards in online discourse and the consequences of violating others' rights [6][14]. Group 4: Implications for Online Governance - This case serves as a significant precedent in the fight against online defamation and reinforces the message that the internet is not a lawless space, urging citizens to respect legal boundaries while exercising their freedom of expression [7][15]. - The ongoing efforts by the government to enhance online governance, including the implementation of new laws and regulations, aim to create a safer digital environment and reduce instances of online violence and defamation [6][15].